Novartis shares plunge 10% after key study miss

Novartis shares fell 10% on Tuesday following a failed clinical study, likely a Phase 3 trial miss. The drop reflects investor concern over pipeline value and near-term growth prospects. The specific drug and trial details are not disclosed in the source, limiting assessment of long-term impact.